1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-64.40%
Cash & equivalents declining -64.40% while Biotechnology shows -0.33% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -8.60%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Current assets growth ≥ 1.5x the Biotechnology median of -9.02%. Joel Greenblatt sees a potential liquidity edge if well allocated.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
≥ 1.5x the Biotechnology median of -5.55%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
289.39%
Payables growth above 1.5x Biotechnology median of 1.92%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
357.80%
Below half Biotechnology median of -2.74%. Joel Greenblatt sees more conservative short-term leverage than peers.
8.45%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
40.87%
Below half Biotechnology median of -1.69%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-9.75%
≥ 1.5x Biotechnology median of -4.31%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-29.17%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-61.26%
≥ 1.5x Biotechnology median of -9.64%. Joel Greenblatt sees stronger equity growth vs. peers.
-64.40%
≥ 1.5x Biotechnology median of -5.55%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
24.32%
Above 1.5x Biotechnology median 1.72%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.